Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Are Rogerofenib and Nilotinib Effective for Advanced Gastrointestinal Stromal Tumor (GIST) Patients who have Already been Given Main Treatments?

  • Ozaslan, Ersin (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
  • Ozkan, Metin (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
  • Bozkurt, Oktay (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
  • Duran, Ayse Ocak (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
  • Ucar, Mahmut (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
  • Eker, Baki (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
  • Berk, Veli (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
  • Karaca, Halit (Department of Medical Oncology, Erciyes University Faculty of Medicine)
  • Published : 2015.06.26
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Demetri GD, Reichardt P, Kang YK, et al (2013). Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 26, 295-302.
  2. Demir L, Ekinci N, Erten C, et al (2013). Does immunohistochemistry provide additional prognostic data in gastrointestinal stromal tumors? Asian Pac J Cancer Prev, 14, 4751-8. https://doi.org/10.7314/APJCP.2013.14.8.4751
  3. Reichardt P, Blay JY, Gelderblom H, et al (2012). Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol, 23, 1680-7. https://doi.org/10.1093/annonc/mdr598
  4. Vadakara J, von Mehren M (2013). Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am, 27, 905-20. https://doi.org/10.1016/j.hoc.2013.07.007
  5. Wu L, Zhang Z, Yao H, et al (2014). Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Drug Des Devel Ther, 30, 2061-7.
  6. Serrano C, George S (2014). Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol, 6, 115-27. https://doi.org/10.1177/1758834014522491